At a time when Medtronic is still promoting a CGM that requires fingerstick calibration, Abbott a leader in CGM technology got some long-awaited good news as finally at long last the FDA has approved the Libre2 and with an iCGM designation for good measure. Per a company issued press release;
“Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes.”
Naturally shares of Dexcom are . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.